Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02754037 · ClinicalTrials.gov registry record
Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study
A clinical trial of Non-alcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD), sponsored by University of California, Davis.
- Active
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT02754037: Active study of Non-alcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD), sponsored by University of California, Davis.
NCT02754037 is a study of Non-alcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) that is active but no longer recruiting, run by University of California, Davis. The registered enrollment target is 120 participants, below the 189-participant average among 16 other Non-alcoholic Steatohepatitis (NASH) trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02754037, a study of Non-alcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD), is active but no longer recruiting, sponsored by University of California, Davis.
- ACTIVE NOT RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate non-invasive imaging techniques for determining liver steatosis (fat), inflammation (abnormal tissue swelling), and fibrosis (abnormal tissue scarring).In addition, the study group will be using other test measures including personal demographics, laboratory blood test results, and imaging measurements to determine the severity of NAFLD (non-alcoholic fatty liver disease), NASH (non-alcoholic steatohepatitis), inflammation, and fibrosis.
Primary Outcome
PET scan parameters correlated with biopsy findings (NAFLD Activity Score as per NASH-CRN)
Conditions Studied
Interventions
- RADIATION Fluorodeoxyglucose (FDG) positron emission tomography (PET)
- OTHER Magnetic resonance imaging (MRI)
- RADIATION PET Explorer
Study Locations (1)
California
- University of California Davis Medical Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2016-04-30 |
| Est. Completion | 2026-06-30 |
What the registry record for NCT02754037 still lists
NCT02754037 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 189-participant average among 16 other Non-alcoholic Steatohepatitis (NASH) trials with a reported enrollment target (37% lower).
The record links to 2 conditions, with Non-alcoholic Steatohepatitis (NASH) appearing as the primary indexed condition, and to 3 interventions - of which Fluorodeoxyglucose (FDG) positron emission tomography (PET) is the first listed.
NCT02754037 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02754037 about?
NCT02754037 is a clinical study titled "Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study". The goal of this study is to evaluate non-invasive imaging techniques for determining liver steatosis (fat), inflammation (abnormal tissue swelling), and fibrosis (abnormal tissue scarring).In addition, the study group will be using other test measures including personal demographics, laboratory blo...
What is the current status of trial NCT02754037?
This trial is currently active not recruiting. The enrollment target is 120 participants. The study started on 2016-04-30. Estimated completion is 2026-06-30.
What conditions does trial NCT02754037 study?
This clinical trial studies the following conditions: Non-alcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease (NAFLD).
What interventions are being tested in trial NCT02754037?
The interventions under investigation include: Fluorodeoxyglucose (FDG) positron emission tomography (PET) (RADIATION), Magnetic resonance imaging (MRI) (OTHER), PET Explorer (RADIATION).
Who is sponsoring clinical trial NCT02754037?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02754037 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Steatohepatitis (NASH)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02754037's enrollment target sits among peer trials
120 9th of 16 higher than 7 of 16 other Non-alcoholic Steatohepatitis (NASH) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-alcoholic Steatohepatitis (NASH) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
RECRUITING · Phase 1
-
Blood Collection Biorepository for Liver Disease Research
RECRUITING
-
A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)
ACTIVE NOT RECRUITING · NA
-
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
ACTIVE NOT RECRUITING · Phase 2
-
A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI